Anti-obesity drug discovery: advances and challenges
Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …
[HTML][HTML] Glucagon-like peptide 1 (GLP-1)
TD Müller, B Finan, SR Bloom, D D'Alessio… - Molecular …, 2019 - Elsevier
Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
[HTML][HTML] Semaglutide lowers body weight in rodents via distributed neural pathways
Semaglutide, a glucagon-like peptide 1 (GLP-1) analog, induces weight loss, lowers
glucose levels, and reduces cardiovascular risk in patients with diabetes. Mechanistic …
glucose levels, and reduces cardiovascular risk in patients with diabetes. Mechanistic …
GLP− 1 receptor agonists for the treatment of obesity: Role as a promising approach
JY Wang, QW Wang, XY Yang, W Yang… - Frontiers in …, 2023 - frontiersin.org
Obesity is a complex disease characterized by excessive fat accumulation which is caused
by genetic, environmental and other factors. In recent years, there has been an increase in …
by genetic, environmental and other factors. In recent years, there has been an increase in …
Dopamine and addiction
RA Wise, MA Robble - Annual review of psychology, 2020 - annualreviews.org
Addiction is commonly identified with habitual nonmedical self-administration of drugs. It is
usually defined by characteristics of intoxication or by characteristics of withdrawal …
usually defined by characteristics of intoxication or by characteristics of withdrawal …
[HTML][HTML] The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in
the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the …
the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the …
Ghrelin, CCK, GLP-1, and PYY (3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB
The efficacy of Roux-en-Y gastric-bypass (RYGB) and other bariatric surgeries in the
management of obesity and type 2 diabetes mellitus and novel developments in …
management of obesity and type 2 diabetes mellitus and novel developments in …
Reverse-translational identification of a cerebellar satiation network
The brain is the seat of body weight homeostasis. However, our inability to control the
increasing prevalence of obesity highlights a need to look beyond canonical feeding …
increasing prevalence of obesity highlights a need to look beyond canonical feeding …
Association of semaglutide with tobacco use disorder in patients with type 2 diabetes: target trial emulation using real-world data
W Wang, ND Volkow, NA Berger, PB Davis… - Annals of Internal …, 2024 - acpjournals.org
Background: Reports of reduced desire to smoke in patients treated with semaglutide, a
glucagon-like peptide receptor agonist (GLP-1RA) medication for type 2 diabetes mellitus …
glucagon-like peptide receptor agonist (GLP-1RA) medication for type 2 diabetes mellitus …
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
A Secher, J Jelsing, AF Baquero… - The Journal of …, 2014 - Am Soc Clin Investig
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2
diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully …
diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully …